June 18, 2019
2019 ASCO Annual Meeting Held in Chicago from May 31-June 4 US Merck’s Keytruda (pembrolizumab) was no doubt the biggest winner among five major checkpoint inhibitors at this year’s American Society of Clinical Oncology (ASCO) confab, touting strong data from...read more